Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDR2 | Q16832 | 4/20 | 0.54 |
| ▸ | BRD4 | O60885 | 4/20 | 0.52 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.50 |
| ▸ | LCK | P06239 | 6/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.49 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 6/20 | 0.48 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | JAK3 | P52333 | 1/20 | 0.48 |
| ▸ | FLT3 | P36888 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5497607 | 0.89 | LCK (0.61) | DDR2BRD4MAP4K1LCKMAPK14 | |
| SCHEMBL5497043 | 0.83 | LCK (0.67) | DDR2BRD4LCKMAPK14KDR | |
| SCHEMBL5504722 | 0.83 | LCK (0.68) | DDR2BRD4MAP4K1LCKMAPK14 | |
| SCHEMBL5488920 | 0.82 | LCK (0.56) | DDR2BRD4MAP4K1LCKMAPK14 | |
| SCHEMBL5494435 | 0.82 | MAP4K1 (0.57) | BRD4MAP4K1STK17AFLT3 | |
| SCHEMBL5490648 | 0.82 | LCK (0.53) | DDR2BRD4MAP4K1LCKMAPK14 | |
| SCHEMBL5502952 | 0.80 | LCK (0.71) | DDR2LCKMAPK14KDRJAK3 | |
| SCHEMBL5498378 | 0.79 | LCK (0.70) | DDR2BRD4LCKMAPK14KDR | |
| SCHEMBL5498684 | 0.79 | LCK (0.62) | DDR2LCKMAPK14KDRJAK2 | |
| SCHEMBL2947423 | 0.78 | LCK (0.78) | BRD4LCKMAPK14KDRJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1836174-B2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2019-10-02 | — | — | EP | claimed |
| EP-1836174-B1 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2013-02-27 | — | — | EP | claimed |
| EP-1836174-A2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC. (US) | 2007-09-26 | — | — | EP | claimed |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | AMGEN INC. | 2007-03-08 | — | — | US | claimed |
| WO-2006039718-A2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2006-04-13 | — | — | WO | claimed |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | AMGEN INC. | 2007-03-08 | — | — | US | disclosed |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | AMGEN INC. | 2007-03-08 | — | — | US | disclosed |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | AMGEN INC. | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | MAP3K1, MAP3K5, MAP3K2 | DDR2 1760/4885BRD4 395/4885MAP4K1 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.